Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
about
Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinomaInhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.Targeting secondary immune responses to cetuximab: CD137 and the outside story.c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.Membrane-Tethered Intracellular Domain of Amphiregulin Promotes Keratinocyte Proliferation.Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts.Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinomaThe EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro.A Novel Hydroxamate-Based Compound WMJ-J-09 Causes Head and Neck Squamous Cell Carcinoma Cell Death via LKB1-AMPK-p38MAPK-p63-Survivin Cascade.Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance.
P2860
Q28534618-5F97AB91-BC14-4D91-8596-1A2519800E4FQ31138064-1990DBAB-29B5-4B47-82EE-79E12EC8D158Q33872496-1707846E-EDB9-4DD9-A990-99F56A533502Q36545205-C176DB45-2B8F-4A37-A134-1BE3D7E3B607Q36677686-FD3BEDEC-6F74-4BDD-A979-D2AA41317B5BQ36693061-F2ADF52D-EF97-4154-A650-03551CBE6582Q37536848-B53A7748-AD94-4303-A5A4-CBDC2DC94B22Q45065769-4486A294-E706-45C8-B55A-A22993A4B347Q51739539-42F7E231-79BD-4B65-A2E9-F44445EBC079Q54964630-EAD73AA9-AACC-4FD2-959E-5B947C4D54F7
P2860
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
@ast
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
@en
type
label
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
@ast
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
@en
prefLabel
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
@ast
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
@en
P2860
P50
P356
P1476
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer
@en
P2093
Mary K Ratay
P2860
P304
P356
10.4161/CBT.20846
P577
2012-08-01T00:00:00Z